Avedro, Inc has has secured $25 million in financing
Avedro, Inc has announced that it has secured $25 million in financing led by Lilly Asia Ventures (LAV)
with major participation from existing investors OrbiMed Advisors, InterWest Partners and HealthQuest Capital.
“Avedro’s mission is to develop non-invasive corneal remodelling treatments that protect and improve vision and dramatically better patients’ lives,” said Reza Zadno, PhD, CEO of Avedro.
“This new funding brings together an exceptional syndicate of investors who are committed to helping us achieve this goal.”